JEREMY BOWEN: Open Payments
NPI 1972615920 · HIGHLAND, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$903 in 42 payments from 13 companies in 2025. Trend: 2023 $149 · 2024 $941 · 2025 $903
Food & beverage: $903
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $257 |
| AstraZeneca Pharmaceuticals LP | 5 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| Novo Nordisk Inc | 4 | $73 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 2 | $31 |
| Amgen Inc. | 2 | $31 |
| Abbott Laboratories | 1 | $25 |
Products named: FARXIGA, UBRELVY, AIRSUPRA, CAPLYTA, VRAYLAR, GEMTESA, REXULTI, MOUNJARO.
Industry payments across IL — which companies pay providers there.
